{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:42:10Z","timestamp":1788964930389,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.7759\/cureus.87085","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:14:11Z","timestamp":1751357651000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary"],"prefix":"10.7759","author":[{"given":"Kyosuke","family":"Seguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira L","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyama","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux J","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, et al.. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023, 389:1851-61. 10.1056\/NEJMoa2309719","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2402691","article-title":"Cancer of unknown primary site","volume":"392","author":"Raghav K","year":"2025","unstructured":"Raghav K. Cancer of unknown primary site. N Engl J Med. 2025, 392:2035-47. 10.1056\/NEJMcp2402691","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Occult Primary. Version 2.2025. (2025). Accessed: June 11, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/occult.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103664","article-title":"Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"9","author":"Hadoux J","year":"2024","unstructured":"Hadoux J, Lamarca A, Grande E, et al.. Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2024, 9:103664. 10.1016\/j.esmoop.2024.103664","journal-title":"ESMO Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2005.15.618","article-title":"Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature","volume":"15","author":"Barbosa SL","year":"2005","unstructured":"Barbosa SL, Rodien P, Leboulleux S, et al.. Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid. 2005, 15:618-23. 10.1089\/thy.2005.15.618","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26283","article-title":"Medullary thyroid microcarcinoma: a population-level analysis of 310 patients","volume":"118","author":"Kazaure HS","year":"2012","unstructured":"Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer. 2012, 118:620-7. 10.1002\/cncr.26283","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4158\/EP151193.CR","article-title":"Sporadic micromedullary thyroid carcinoma with bone metastases at diagnosis: a case report and review of the literature","volume":"3","author":"Choudhary C","year":"2017","unstructured":"Choudhary C, Scharpf J, Nasr C. Sporadic micromedullary thyroid carcinoma with bone metastases at diagnosis: a case report and review of the literature. AACE Clin Case Rep. 2017, 3:e35-8. 10.4158\/EP151193.CR","journal-title":"AACE Clin Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah V","year":"2020","unstructured":"Subbiah V, Cote GJ. Advances in targeting RET-dependent cancers. Cancer Discov. 2020, 10:498-505. 10.1158\/2159-8290.CD-19-1116","journal-title":"Cancer Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu B","year":"2022","unstructured":"Xu B, Fuchs TL, Ahmadi S, et al.. International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol. 2022, 40:96-104. 10.1200\/JCO.21.01329","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5540-5","article-title":"Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls","volume":"19","author":"Beukhof CM","year":"2019","unstructured":"Beukhof CM, Brabander T, van Nederveen FH, et al.. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer. 2019, 19:325. 10.1186\/s12885-019-5540-5","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104524","article-title":"DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: a narrative review","volume":"204","author":"Peddio A","year":"2024","unstructured":"Peddio A, Pietroluongo E, Lamia MR, et al.. DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: a narrative review. Crit Rev Oncol Hematol. 2024, 204:104524. 10.1016\/j.critrevonc.2024.104524","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370694-a-case-of-micro-medullary-thyroid-carcinoma-presenting-as-cancer-of-unknown-primary","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:14:12Z","timestamp":1751357652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370694-a-case-of-micro-medullary-thyroid-carcinoma-presenting-as-cancer-of-unknown-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.87085","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}